Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12398
Title: Lamotrigine can be beneficial in patients with Dravet syndrome.
Authors: Dalic, Linda;Mullen, Saul A;Roulet Perez, Eliane;Scheffer, Ingrid E
Affiliation: Austin Health, Melbourne, Vic., Australia.
Issue Date: 22-Sep-2014
Citation: Developmental Medicine and Child Neurology 2014; 57(2): 200-2
Abstract: Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drugs (AED). Lamotrigine (LTG), an AED that is effective for both focal and generalized seizures, has been reported to aggravate seizures in Dravet syndrome. Therefore, LTG is usually avoided in Dravet syndrome. We describe two adults and a child with Dravet syndrome in whom LTG resulted in decreased seizure duration and frequency. This benefit was highlighted in each patient when LTG was withdrawn after 6 to 15 years, and resulted in an increased frequency of convulsive seizures together with longer seizure duration. A 25-year-old male required hospital admission for frequent seizures for the first time in 7 years, 6 weeks after ceasing LTG. Reintroduction of LTG improved seizure control, suggesting that in some patients with Dravet syndrome, LTG may be beneficial.
Internal ID Number: 25243660
URI: http://ahro.austin.org.au/austinjspui/handle/1/12398
DOI: 10.1111/dmcn.12593
URL: http://www.ncbi.nlm.nih.gov/pubmed/25243660
Type: Journal Article
Subjects: Adolescent
Adult
Anticonvulsants.therapeutic use
Epilepsies, Myoclonic.drug therapy.physiopathology
Humans
Male
Seizures.drug therapy.physiopathology
Triazines.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.